official impact factor

2.72

Advanced search

The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481]

The FIELD Study Investigators

Correspondence: The FIELD Study Investigators tony@ctc.usyd.edu.au

Cardiovascular Diabetology 2004, 3:9 doi:10.1186/1475-2840-3-9

Accesses

Last 30 days: 69 accesses
Last year: 740 accesses
All time: 11668 accesses

Cited by

BioMed Central: 3 citations

Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481]

Cardiovascular Diabetology 2005, 4:13 (22 August 2005)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central

Statins research unfinished saga: desirability versus feasibility

Enrique Z Fisman, Yehuda Adler, Alexander Tenenbaum Cardiovascular Diabetology 2005, 4:8 (7 June 2005)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central

Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?

Alexander Tenenbaum, Enrique Z Fisman Cardiovascular Diabetology 2004, 3:10 (1 December 2004)

Abstract | Full text | PDF | PubMed | Cited on BioMed Central

Google Scholar: View citations

PubMed Central: View citations